TIDMBYOT
RNS Number : 2920Z
Byotrol PLC
14 December 2017
14(th) December, 2017
Byotrol plc
INTERIM RESULTS
FOR THE SIX MONTHSED 30 SEPTEMBER 2017
Byotrol plc ('Byotrol', the 'Group' or the 'Company') the AIM
listed anti-microbial technology company, is pleased to present its
unaudited interim results for the six months ended 30 September
2017.
Highlights
-- Results in-line with previous guidance, namely improved sales
and gross margin compared to H1 2016
o Sales at GBP934k versus GBP909k in H1 2016; gross profit
GBP343k versus GBP283k in H1 2016
o Operating costs increased by 17%, largely reflecting a 62%
increase in sales and marketing spend. Operating loss before share
based payments therefore increased to GBP592k from GBP514k in H1
2016
-- Continued progress in three key strategic initiatives, including:
o US surface care - Federal approval complete, individual state
approvals now very advanced, likely to complete February 2018.
Board is confident in securing a US supermarket trial in mid
2018.
o EU surface care - third-party FMCG testing continues;
increased resource investment in the project by our
commercialisation partner Solvay
o Hand hygiene - now launched in NHS under new brand "Invirtu;"
encouraging signs of sales progress
-- Strong balance sheet. Successful fund raise completed August
2017, reinvigorated shareholder register with new institutional
support. Cash reserves of GBP4.8m at period end.
-- Funds being put to work on hiring sales and marketing
professionals. New US leadership in place, with new VP Sales and
Marketing hired, with excellent background in new product
commercialisation, gained at Kimberly-Clark, Coca-Cola
-- Confidence in outlook for full year, although dependent on
closing alliances, partnerships and sales before year end.
Commenting on the results, David Traynor, Chief Executive of
Byotrol, said:
Having spent the last three years redeveloping our technologies
for the new regulatory regimes, we are now investing heavily in
sales and marketing, including extensive redevelopment of product
propositions. To that end we were very pleased that investors
further supported our strategy with a GBP4.6m financing in the
period; we believe that we now have the resources to fully execute
our growth strategy.
Enquiries:
Byotrol plc
David Traynor - Chief Executive 01925 742 000
finnCap
Geoff Nash/Kate Bannatyne - Corporate Finance 020 7220 0500
Stephen Norcross/Richard Chambers - Corporate Broking
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a leading anti-microbial
technology company, operating globally in the Food, Industrial,
Healthcare and Consumer sectors, providing low toxicity products
with a broad-based and long-lasting efficacy across all microbial
classes; bacteria, viruses, fungi, moulds, mycobacteria and
algae.
Powerful, long-lasting and gentle, Byotrol's products can be
used stand-alone or as ingredients within existing products, where
Byotrol can significantly improve their performance, especially in
personal hygiene, domestic and industrial disinfection, odour
control, food production and food management.
Founded in 2005, the Company develops technologies that create
easier, safer and cleaner lives for everyone.
For more information, please go to www.byotrol.co.uk
Chief Executive's Report
We continue to make really good progress, re-positioning the
Company into new markets with new, regulatory-approved
technologies, new products and new propositions. In parallel with
this, we continue to service the legacy businesses where the
revenues clearly contribute to central costs.
All three strategic initiatives - US consumer surface care, EU
surface care with Solvay and alcohol-free hand sanitisers - are
progressing nicely, with further validation that our propositions
meet customer needs at price points that generate good margin.
Our pet/animal and consumer business is already benefiting from
the new technologies with good levels of interest being generated
in surface care and hand hygiene, including one brand re-launch
("Byopet") into Asia, plus one new brand launch ("Invirtu") into
the UK NHS and healthcare markets. Further detail is given in the
segmental commentary below. We hope our next big launch will be
into US consumer markets via mass-market retail.
Reported numbers for this period follow a similar profile to H1
2016, with a small increase in sales and gross profit compared to
the previous year, reflecting continued improvements in
efficiencies, but a larger operating loss in the period relative to
the previous year as we increase spend on sales and marketing. The
outlook for the full year will, as per last year, depend on us
closing larger ticket deals in the second half of the year,
something we remain optimistic about achieving.
Results by segment
Professional care
H1 revenues fell slightly to GBP546k from GBP580k in H1 2016 and
gross profit fell to GBP129k from GBP161k.
We are now gradually transitioning our Professional product
offer away from food markets and into health-oriented markets,
where (1) our technologies are differentiated and (2) customers are
more willing to pay higher prices for the long-lasting claims that
our products can make. Food and jansan customers are still being
serviced efficiently and proactively and new customers are being
sought, but we are now expending less resource in this area than
historically.
Central to the change programme underway in Professional is a
formal process of market analysis and proposition development. We
have completed one process already, leading to the relaunch of
alcohol-free hand hygiene products under a new brand "Invirtu" into
the UK NHS in September, directly and via third party agents. We
have great hopes for the product as we believe it has few genuine
competitors and we hope will be a strong bridgehead into healthcare
and other markets where high performance hand-hygiene products are
required. Total sales since launch have been a little behind plan
as we get used to working with the NHS supply chain, but rate of
sales are picking up rapidly now, with our hand sanitisers being
used in over 80 UK hospitals, one (500 bed) total-trust conversion
(from competitor's alcohol-based product), four partial trust
conversions and six trials underway.
Based on our presence in the NHS we are also being asked to
white label and co-brand the core formulations with large UK
hygiene, healthcare and facilities management companies. Foremost
among those is our relationship with Rentokil and its Ultraprotect
brand, which continues to progress well.
Next step is to reposition our Professional surface care offer
and we are mid-way through the required analytical process. Amongst
other things we see many opportunities to leverage surface care
products into Invirtu customers in the healthcare market.
Petcare
H1 revenues fell slightly to GBP278 k from GBP295k in H1 2016,
but gross profit rose by 12% to GBP105k
This segment continues to perform solidly, with progress in
gross margin and new customer acquisition, particularly
overseas.
The new and improved 'Byopet' range (pet environment and pet
grooming products) has now been launched to trade at the China
International Pet Show (CIPS) in Shanghai, with updated branding
and optimised product range. Production of the new range is on
track and first orders should be despatched before end of Q4. A
number of high quality leads were captured at CIPS from several new
territories including China, Australia, UAE and India.
We have also made good progress in launching hand sanitisers
into animal health markets, including a new agreement signed with
Medimark Scientific Limited, a premier distributor of hygiene
products into vetcare markets. Medimark launched the product under
the Esense brand (with Byotrol as an ingredient brand), to the UK
veterinary market in November at the London Vet Show.
Consumer
H1 revenues and gross profit increased to GBP110k from GBP34k in
H1 2016.
In surface care in the UK, sales in Tesco (via our license with
Robert Mcbride plc) of Byotrol ingredient-branded surface sprays
continue to increase. We have a good relationship with Mcbrides and
are looking to do more with them, particularly with our improved
technology platforms.
In surface care in the US, we are making very rapid progress
with the EPA registered long-lasting anti-microbial trigger spray
for US domestic consumers. In particular, we have:
-- received regulatory approval from over 20 individual US
states and expect the remainder to be completed by February 2018.
This is the second regulatory step to complete following the formal
(federal) EPA approval completed in August this year
-- secured a high-quality supply chain, with packaging agreed
and main plant trials due in January 2018.
-- generated in-principal approval from 2 leading US retail
chains - including one mass-market retailer - for two-month trials
in mid 2018. A successful trial should lead to national
roll-out.
-- began conversations with potential licensees/partners
targeting business users of the product
In surface care in Europe, we continue to market the Actizone
formulation to FMCGs with our partner Solvay. The Solvay team is
generally now taking the commercial lead as they have more
resources to service customer requirements and more senior
relationships with those customers. Several discussions are
ongoing, potential commercial wins are substantial and Solvay is
committing more and more resources to the initiative, but the
timing of revenue and product on shelf is uncertain.
In consumer-targeted hand hygiene,
-- We are now starting to receive royalties in the US from our
license with Advanced Hygienics LLC, which is manufacturing and
distributing alcohol-free hand sanitisers under the American Red
Cross brand, targeted to US consumers via retail. We are excited
about the progress being made here.
-- Boots has now transitioned across to the new formulation
alcohol-free hand sanitiser and we are now back on shelf in most
Boots stores in their own-brand healthcare section. We are now in
discussions with other high street retailers to put our products in
their stores under their or our brand.
Fundraising and Convertible Loan Note redemption
The Company was very pleased to complete a GBP4.6m (net of
expenses) fundraising on 5 September 2017 from new and existing
equity investors. The funds are being invested in sales and
marketing, especially in the US, and will give us a stronger
balance sheet to support commercial deal negotiation
In parallel with the refinancing and in response to many
investors wishes, the Company has now redeemed its outstanding
GBP380k Convertible Loan Notes. This exercise was completed in
early September and resulted in 100% conversion of the notes by
investors into Byotrol share capital.
Outlook
We recognise that we remain something of a jam-tomorrow stock,
with financial progress still partially reliant on one-off
technical development and exclusivity fees. However, those deals
are serving us well - limiting cash burn, generating margin,
financing technical development and supporting multiple levels of
proposition redevelopment for the new regulatory-driven world we
are operating in.
Having been focussed largely on technical development over the
last few years we are now able to concentrate on sales and
marketing and are making good progress in putting in place all the
right things to deliver product sales and technology sales,
including building a sales and marketing team to cover both
domestic and export markets. We are obviously doing all we can to
increase market presence, but we also need the increased sales to
generate economies of scale and quality of supply chain - one of
our historic challenges.
The recent fund raising of GBP4.6m, net of expenses, has given
us the financial resources to grow and has secured some first-class
new investors on our shareholder register. Our challenge now is to
execute the commercial plan and deliver to the financial targets.
The team is confident it will do so and looks forward to
substantial progress in the second half of the financial year. We
continue to look to our long-term future with confidence and
excitement.
David Traynor
Chief Executive
Byotrol plc
UNAUDITED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
for the 6 month period ended 30 September 2017
6 mths 6 mths Year ended
ended ended 31 March
30 September 30 September
2017 2016 2017
GBP GBP
REVENUE 934,076 909,073 3,127,182
Cost of sales (590,692) (625,601) (1,375,553)
------------------------ ------------------------ ------------------------
GROSS PROFIT 343,384 283,472 1,751,629
Sales and marketing costs (322,566) (198,312) (386,032)
Research and development costs (194,905) (242,737) (412,269)
Other administrative costs (417,472) (356,035) (926,501)
------------------------ ------------------------ ------------------------
OPERATING LOSS / (PROFIT) BEFORE
SHARE-BASED
PAYMENTS DEPRECIATION AND
AMORTISATION (591,559) (513,612) 26,827
Share based compensation (38,727) (15,453) (92,722)
Expense on amendment of convertible
loan note terms (26,000) - -
Amortisation (94,794) (33,936) (94,204)
Depreciation (9,060) (5,102) (15,504)
------------------------ ------------------------ ------------------------
OPERATING LOSS (760,140) (568,103) (175,603)
Finance income - 83 184
Finance costs (44,841) (8,270) (16,443)
Research and development (R & D) tax
credits - - 65,435
------------------------ ------------------------ ------------------------
LOSS BEFORE TAX (804,981) (576,290) (126,427)
Taxation - -
-
------------------------ ------------------------ ------------------------
LOSS FOR THE FINANCIAL YEAR (804,981) (576,290) (126,427)
------------------------ ------------------------ ------------------------
OTHER COMPREHENSIVE INCOME, NET OF
TAX
Other comprehensive income to be
reclassified
to profit or loss in subsequent
periods:
Currency translation difference (10,859) - 20,520
------------------------ ------------------------ ------------------------
Other comprehensive income/(expense) - - 20,520
------------------------ ------------------------ ------------------------
TOTAL COMPREHENSIVE LOSS FOR THE
YEAR (815,840) (576,290) (105,907)
============ ============ ============
Basic and fully diluted loss per
share
- pence (0.28) (0.21) (0.05)
Byotrol plc
UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As at 30 September 2017
As at 30 As at 30 As at 31
September September March
2017 2016 2017
GBP GBP GBP
ASSETS
Non-current assets
Property, plant and equipment 35,007 18,926 44,067
Intangible assets 675,461 579,321 690,987
------------------------ ------------------------ ------------------------
710,468 598,247 735,054
Current assets
Inventories 126,416 154,670 200,795
Trade and other receivables 695,617 583,618 860,236
Cash and cash equivalents 4,834,477 525,752 951,088
------------------------ ------------------------ ------------------------
5,656,510 1,264,040 2,012,119
------------------------ ------------------------ ------------------------
6,366,978 1,862,287 2,747,173
============ ============ ============
LIABILITIES
Current liabilities
Trade and other payables 519,737 404,961 750,074
Convertible loan notes - 359,975 -
------------------------ ------------------------ ------------------------
519,737 764,936 750,074
-------------------- ------------------------ ------------------------
Long term liabilities
Convertible loan notes - - 352,096
------------------------ ------------------------ ------------------------
- - 352,096
------------------------ ------------------------ ------------------------
Equity
Share capital 1,007,092 670,129 670,129
Share premium account 27,522,864 22,849,284 22,849,284
Merger reserve 1,064,712 1,064,712 1,064,712
Other reserves (36,587) 23,053 43,573
Retained deficit (23,710,840) (23,509,827) (22,982,695)
------------------------ ------------------------ ------------------------
TOTAL EQUITY 5,847,241 1,097,351 1,645,003
------------------------ ------------------------ ------------------------
TOTAL EQUITY AND LIABILITIES 6,366,978 1,862,287 2,747,173
============ ============ ============
Byotrol plc
UNAUDITED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
for the 6 month period ending 30 September 2017
Retained earnings
Share Share premium Merger reserve Other reserves reserve
capital GBP GBP GBP GBP Total equity
GBP GBP
At 1 April
2016 670,129 22,849,284 1,064,712 23,053 (22,948,990) 1,658,188
Loss for the
period - - - - (576,290) (576,290)
Currency - - - - - -
translation
difference
---------------------- ---------------------- ----------------------- ---------------------- ---------------------- ----------------------
Total
comprehensive
loss for the
period - - - - (576,290) (576,290)
Share based
payments - - - - 15,453 15,453
-------------------- ---------------------- ------------------- ---------------------- ---------------------- -----------------------
Balance as at
30 September
2016 670,129 22,849,284 1,064,712 23,053 (23,509,827) 1,097,351
============= =============== ============= =============== =============== ===== ==========
Profit for the
period - - - - 449,863 449,863
Currency
translation
difference - - - 20,520 - 20,520
---------------------- ---------------------- ----------------------- ----------------------- ---------------------- ----------------------
Total
comprehensive
profit for
the period - - - 20,520 449,863 470,383
Share based
payments - - - - 77,269 77,269
-------------------- ---------------------- ------------------- ---------------------- ---------------------- -----------------------
Balance as at
31 March 2017 670,129 22,849,284 1,064,712 43,573 (22,982,695) 1,645,003
============= =============== ============= =============== =============== ===============
Byotrol plc
UNAUDITED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
for the 6 month period ending 30 September 2017
Retained earnings
Share Share premium Merger reserve Other reserves reserve
capital GBP GBP GBP GBP Total equity
GBP GBP
Loss for the
period - - - - (804,981) (804,981)
Currency
translation
difference - - - (10,859) - (10,859)
---------------------- ---------------------- ----------------------- ---------------------- ---------------------- ----------------------
Total
comprehensive
loss for the
period - - - (10,859) (804,981) (815,840)
Share issue 309,820 4,647,293 - - - 4,957,113
Share issue
costs - (380,858) - - - (380,858)
Share based
payments - - - - 38,727 38,727
Conversion of
convertible
loan notes 27,143 407,145 - (69,301) 38,109 403,096
-------------------- ---------------------- ------------------- --------------------- ---------------------- -----------------------
Balance as at
30 September
2017 1,007,092 27,522,864 1,064,712 (36,587) (23,710,840) 5,847,241
============= =============== ============= ============== ============== ===== ===== ==========
Byotrol plc
UNAUDITED CONSOLIDATED CASH FLOW STATEMENT
for the 6 month period ended 30 September 2017
6 mths 6 mths Year ended
ended ended 31 March
30 30 2017
September September
2017 2016
GBP
GBP GBP
CASH FLOW FROM OPERATING ACTIVITIES
Loss for the period before tax (804,981) (576,290) (126,427)
Adjustments for:
Share based payments 38,727 15,453 92,722
Expense on amendment of 26,000 - -
convertible
loan note terms
Depreciation 9,060 5,102 15,504
Amortisation 94,794 33,936 94,204
Loss on disposal of property,
plant and equipment - - 139
Impairment of intangible assets - - 23,586
Finance income - (83) (184)
Finance costs 44,841 8,270 16,443
Changes in working capital
Decrease in inventories 74,379 65,648 19,523
Decrease in trade and other
receivables 164,619 200,263 (76,355)
(Decrease) in trade and other
payables (230,337) (185,763) 159,350
------------------------ ------------------------ ------------------------
CASH GENERATED / (USED) IN OPERATING
ACTIVITIES (582,898) (433,464) 218,505
CASH FLOWS FROM INVESTING ACTIVITIES
Payments to acquire property,
plant and equipment - (1,606) (37,288)
Payments to acquire intangible
assets 79,268 (48,179) (243,699)
Finance income - 83 184
------------------------ ------------------------ ------------------------
NET CASH USED IN INVESTING
ACTIVITIES (79,268) (49,702) (280,803)
------------------------ ------------------------ ------------------------
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds on issue of ordinary 4,957,112 - -
shares
Share issue costs (380,858) - -
Interest paid (19,841) (8,270) (24,322)
------------------------ ------------------------ ------------------------
NET CASH INFLOW /(OUTFLOW) FROM
FINANCING 4,556,413 (8,270) (24,322)
------------------------ ------------------------ ------------------------
Net increase/(decrease) in cash
and cash equivalents 3,894,247 (491,436) (86,620)
Cash and cash equivalents at the
beginning of the financial year 951,088 1,017,188 1,017,188
Effect of foreign exchange rate
changes (10,858) - 20,520
------------------------ ------------------------ ------------------------
Cash and cash equivalents at the
end of the financial year 4,834,477 525,752 951,088
============ ============ ============
Byotrol plc
NOTES TO THE INTERIM FINANCIAL STATEMENTS
for the 6 month period ended 30 September 2017
1. Basis of preparation
The financial statements have been prepared in accordance with
the AIM rules, international financial reporting standards ("IFRS")
as adopted by the European Union that are applicable to the Group's
statutory accounts for the year ended 31(st) March 2017 and the
applicable provisions of the Companies Act 2006. The interim
financial statements are unaudited and were approved by the
Directors on 13th December 2017. The information set out herein is
abbreviated and does not constitute statutory accounts within the
meaning of Section 434 of the Companies Act 2006. The results for
the year ended 31 March 2017 are in abbreviated form and have been
extracted from the published financial statements. These were
audited and reported upon without qualification by Mazars LLP and
did not contain a statement under Section 498(2) or (3) of the
Companies Act 2006. Statutory accounts for the financial year ended
31 March 2017 have been filed with the Registrar of Companies.
The Group has not applied IAS 34, Interim Financial Reporting,
which is not mandatory for UK Groups, in the preparation of these
interim financial statements.
The Company is a limited liability company incorporated and
domiciled in England & Wales and whose shares are quoted on
AIM, a market operated by The London Stock Exchange. The
consolidated financial information of Byotrol plc is presented in
Pounds Sterling (GBP), which is also the functional currency of the
parent.
2. Going concern
The Group has continued to incur losses in the period to 30
September 2017, but had, at the period end, cash reserves and net
assets of GBP4,834,477 and GBP5,847,241. Byotrol plc has prepared
interim financial statements on a going concern basis, which
assumes the Group will continue in operational existence for the
foreseeable future.
3. Segmental information
The Group has three reportable segments; being Professional
(including food service, food manufacturing, industrial and
health), Consumer and Pet. This disclosure correlates with the
information which is presented to the Group's Chief Decision Maker,
the Board. The Group's revenue, result before taxation and net
assets were all derived from its principal activities.
The first segment concerns the professional sector incorporating
business to business sales into food and beverage, healthcare and
facilities management. The second segment concerns the consumer
sector and primarily revenue generated from licence agreements with
third parties for the manufacture and sale of products
incorporating Byotrol technology. The third sector is Petcare,
where finished goods are manufactured and sold into the companion
animal sector.
The Group operates in different geographic locations. The
revenue generated from the different geographic locations is
analysed separately into the information below.
Continuing operations
Professional Consumer Pet Total
6 months ended 30 GBP GBP
September 2017 GBP GBP
REVENUE
United Kingdom 534,185 87,196 120,087 741,468
North America 601 22,401 - 23,002
Rest of World 12,052 - 157,554 169,606
------------------------ ------------------------ ------------------------ ------------------------
Total revenue 546,838 109,597 277,641 934,076
Cost of sales (417,983) - (172,709) (590,692)
------------------------ ------------------------ ------------------------ ------------------------
Gross profit 128,855 109,597 104,932 343,384
=========== =========== =========== ===========
Centrally incurred income and expenditure not attributable to individual segments:
Sales and
marketing costs (322,566)
Research and
development costs (194,905)
Other
administrative
costs (417,472)
Depreciation and
amortisation (103,854)
Share based
payments (38,727)
Expense on
amendment of
convertible loan
note terms (26,000)
Finance income -
Finance costs (44,841)
------------------------
Loss before tax (804,981)
===========
3. Segmental information (continued)
Continuing operations
Professional Consumer Pet Total
6 months ended GBP GBP GBP GBP
30 September
2016
REVENUE
United Kingdom 578,755 33,526 97,659 709,940
North America 1,659 - - 1,659
Rest of World - - 197,474 197,474
------------------------ ------------------------ ------------------------ ------------------------
Total revenue 580,414 33,526 295,133 909,073
Cost of sales (419,008) - (206,593) (625,601)
------------------------ ------------------------ ------------------------ ------------------------
Gross Profit 161,406 33,526 88,540 283,472
=========== =========== =========== ===========
Central income and expenditure not attributable to individual segments:
Sales and
marketing
costs (198,312)
Research and
development
costs (242,737)
Other
administrative
costs (356,035)
Depreciation
and
amortisation (39,038)
Share based
payments (15,453)
Finance income 83
Finance Costs (8,270)
------------------------
(576,290)
===========
Continuing operations
Professional Consumer Pet Total
Year ended 31 GBP GBP GBP GBP
March 2017
REVENUE
United Kingdom 1,151,840 1,146,956 408,408 2,707,204
North America 25,228 5,402 - 30,630
Rest of World 3,763 - 385,585 389,348
------------------------ ------------------------ ------------------------ ------------------------
Total revenue 1,180,831 1,152,358 793,993 3,127,182
Cost of sales (850,699) - (524,854) (1,375,553)
------------------------ ------------------------ ------------------------ ------------------------
Gross Profit 330,132 1,152,358 269,139 1,751,629
=========== =========== =========== ===========
Central income and expenditure not attributable to individual segments:
Sales and
marketing
costs (386,032)
Research and
development
costs (412,269)
Other
administrative
costs (926,501))
Depreciation
and
amortisation (109,708)
Share based
payments (92,722)
Finance income 184
Finance Costs (16,443)
Research and
development
(R&D) tax
credits 65,435
------------------------
(126,427)
===========
4. Loss per share
The loss per ordinary share is based on the losses for the
period of GBP804,981 (six months ended 30 September 2016:
GBP576,290; twelve months ended 31 March 2017: GBP126,427) and the
weighted average number of ordinary shares in issue during the
period of 287,992,349 (six months ended 30 September 2016;
268,051,565, twelve months ended 31 March 2017: 268,051,565).
The loss for the period and the weighted average number of
ordinary shares for calculating the diluted earnings per share for
the six months ended 30 September 2017 and for the comparative
periods are identical to those used for the basic earnings per
share. This is because the outstanding share options would have the
effect of reducing the loss per ordinary share and would therefore
not be dilutive.
5. Taxation
No liability to UK corporation or overseas income taxes arises
for the period due to losses incurred. The Directors have assessed
the position in relation to deferred tax and concluded that no
provision or asset should be created at this stage in respect of
deferred tax in view of the timescale and uncertainty of the
recovery of tax losses. This position will be reviewed again at 31
March 2018.
6. Interim announcement
The interim report was released on 14 December 2017. It is also
available on the Company's website, www.byotrol.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR BRBDDSSBBGRX
(END) Dow Jones Newswires
December 14, 2017 02:00 ET (07:00 GMT)
Byotrol (LSE:BYOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Byotrol (LSE:BYOT)
Historical Stock Chart
From Apr 2023 to Apr 2024